請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66529
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳俊忠 | |
dc.contributor.author | Shao-Yin Chen | en |
dc.contributor.author | 陳韶瑩 | zh_TW |
dc.date.accessioned | 2021-06-17T00:40:46Z | - |
dc.date.available | 2014-02-16 | |
dc.date.copyright | 2012-02-16 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2012-01-19 | |
dc.identifier.citation | 1.Adrian K. K. Teo and Ludovic Vallier(2010)Emerging use of stem cells in regenerative medicine. Biochem. J. 428: 11–23.
2. Ahmed H,Jafary FH, Kiani J.(2007)Outcomes of primary percutaneous coronary intervention at a joint commission international accredited hospital in a developing country – can good results, possibly similar to the west, be achieved? J Invasive Cardiol.;19:417–23. 3. Alderman L.(2009)Bargaining down the medical bills. NY Times.;14:2009. 4. Alleman BW, Luger T, Reisinger HS, Martin R, Horowitz MD, Cram P(2011)Medical tourism services available to residents of the United States. J Gen Intern Med. 26(5):492-7. Epub 2010 Dec 15. 5. American Medical Association(2009)New AMA guidelines on medical tourism; 6. Barclay E.(2009)Stem-cell experts raise concerns about medical tourism. Lancet.;373:883–4. 7. Bauer JC.(2009)Medical tourism: wave of the future in a world of hurt? Healthc Financ Manage. 63:36–8. 40, 2. 8.Blazar BR ,Murphy WJ (1999) New strategies for preventing graft‑versus‑host disease. Curr Opin Immunol 11: 509–515 9. Boheler KR ,Wobus AM. (2005) Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev. 85(2):635-78. 10.Burt, R. K., Loh, Y., Pearce, W., Beohar, N., Barr, W. G., Craig, R., Wen, Y., Rapp, J. A. and Kessler, J. (2008) Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA, 299, 925-936 11. Canales MT, Kasiske BL, Rosenberg ME.(2006)Transplant tourism: Outcomes of United States residents who undergo kidney transplantation overseas. Transplantation.;82:1658–61. 12.Caplan A, Levine P (2010) Hope, hype, and help: ethically assessing the growing market in stem cell therapies. Am J Bioeth 10: 24–25 13. Caulfield T, Nisbet M, Rachul C,Zarzeczny A.(2010)cell clinics in the news. Nat Biotechnol.;28(12):1243-6. Stem 14. Caulfield T, Nisbet M, Rachul C,Zarzeczny A.(2010)Nat Biotechnol..Stem cell clinics in the news.;28(12):1243-6. 15. Caulfield T ,Lau D, Ogbogu U, Taylor B, Stafinski T, Menon D, (2008) Stem cell clinics online: the direct‑to‑consumer portrayal of stem cell medicine. Cell Stem Cell 3: 591–594 16. Chen HC, Kuo HC, Chung KP, Chang S, Su S, Yang MC(2010)Classification and comparison of niche services for developing strategy of medical tourism in Asian countries. Int Surg. ;95(2):108-16 17.Cohen CB, Cohen PJ(2010)International stem cell tourism and the need for effective regulation part I: stem cell tourism in Russia and India: clinical research, innovative treatment, or unproven hype? Kennedy Inst Ethics J 20: 27–49 18. Cyranoski D(2010)Korean deaths spark inquiry. Nature.;468(7323):485. 19.David J. Collis and Cynthia A.(2008)Montgomery Competing on Resources 140 Harvard Business Review | July–August 140-150 20. Deloitte Consulting Inc.(2009)Medical tourism: update and implications- 2009 report;. 21. Donald C. Hambrick and James W.(2005)Are you sure you have a strategy? Academy of Management Executive, Vol. 19, No. 4 Reprinted from 2001, Vol. 15, No. 4 22. Fonkych K, Melnick GA.(2008)Hospital pricing and the uninsured: do the uninsured pay higher prices? Health Aff.;27:w116–22. 23. Forrest DL ,Gallagher G (2007) Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer 109: 84–92 24. Francis T.(2008)Medical tourismis still small. TheWall Street Journal. 25. Frost & Sullivan US stem cell market(2008)United States 26. Ginsburg P.(2007)Shopping for price in medical care. Health Aff ;26:w208. 27.Heejung J, Yi H (2011) South Korea back in stem cell spotlight with new treatment. Reuters, 7 July. www.reuters.com 28.Horowitz MD, Rosensweig JA.(2008)Medical tourism vs. traditional international medical travel: a tale of two models. International Medical TravelJournal.;1-14. 29. Horowitz MD, Rosensweig JA.(2007)Medical tourism–health care in the global economy. Physician Exec. 33(24–6):8–30. 30. Horowitz MD, Rosensweig JA, Jones CA.(2007)Medical tourism: globalization of the healthcare marketplace. Medscape General Medicine.;9:33. 31. Horowitz MD, Rosenweig JA.(2007)Medical tourism – health care in the global economy. Physician Exec.;33:24. 32. Hutchinson LA, Regenberg ACAC, Schanker B, Mathews DJ (2009) Medicine on the fringe: stem cell-based interventions in advance of evidence. Stem Cells 9: 2312–2319 33.Hyun I et al (2008) New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell 3: 607–609 34. Hyun I(2010)Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges. J Law Med Ethics. ;38(2):277-85. 35. Jones JW, McCullough LB.(2007)What to do when a patient’s international medical care goes south. J Vasc Surg.;46:1077–9. 36.Kiatpongsan S, Sipp D (2009) Medicine. Monitoring and regulating offshore stem cell clinics. Science 323: 1564–1565 37. Konrad W.(2009)Going abroad to find affordable healthcare. The New York Times;Sect. 6. 38. Levine AD , Ryan KA, Sanders AN, Wang DD (2010) Tracking the rise of stem cell tourism. Regen Med 5: 27–33 39.Lindvall O, Hyun I (2009) Medical innovation versus stem cell tourism. Science 324: 1664–1665 40. MacReady N.(2009)The murky ethics of stem-cell tourism. Lancet Oncol.;10:317–8. 41. Master Z, Resnik DB.(2011)Stem-cell tourism and scientific responsibility. Stem-cell researchers are in a unique position to curb the problem of stem-cell tourism. EMBO Rep;12(10):992-5 42.Michael E. Porter(2008)The five competitive forces that shape strategy Harvard Business Review 79-93 43.Michael E. Porter,(1998) Competitive Advantage: Creating and Sustaining Superior Performance (The FreePress,). 44.Michael E.(1980)Porter’s book Competitive Strategy: Techniques for Analyzing Industries and Competitors (Free Press,). 45. Milstein A, Smith M.(2006)America’s new refugees–seeking affordable surgery offshore. N Engl J Med.;355:1637–40. 46. Milstein A, Smith M (2007)Will the surgical world become flat? Health Aff ;26:137–41. 47.Moss RW (2005) Patient Perspectives: Tijuana cancer clinics in the post-NANAFTATA era. Integr Cancer Ther 4: 65–86 48.Nistor, G. I., Totoiu, M. O., Haque, N., Carpenter, M. K. and Keirstead, H. S. (2005) Human embryonic stem cells differentiate into oligodendrocytes in high purity and myelinate after spinal cord transplantation. Glia 49, 385-396 49.Ochiya, T., Yamamoto, Y. and Banas, A (2009) Commitment of stem cells into functional hepatocytes. Differentiation 79, 65-73 50. Paul Evers (2009) Advances in the stem cell industry: the future impact of innovation, and an evaluation of the commercial landscape 51.Resnik DB (1999) Privatized biomedical research, public fears, and the hazards of government regulation: lessons from stem cell research. Health Care Anal 7: 273–287 52.Rodriguez V (2005) Material transfer agreements: open science vs. proprietary claims. Nat Biotechnol 23: 489–491 53. Rotenberk L. Medical tourism.(2008)As the world flattens, US hospitals expand their global reach. Hosp Health Netw.;82:14. 54.Saha, K. and Jaenisch, R.(2009)Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell 5, 584-595 55.Stem Cell Therapeutics(2008)KALORAMA INFORMATION MARKET INTELLIGENCE | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66529 | - |
dc.description.abstract | 幹細胞旅遊業是一個新的術語用來描述由異國的私人醫院給予國際病患幹細胞治療的一種風潮。而這些治療其實在該病患所屬國籍的國家內並未被正式核可執行的。這些幹細胞治療在安全性或效能上都仍是有待釐清的,然而目前文獻在此新興產業上沒有任何策略分析著墨,台灣在這個全球性風潮中可扮演的策略定位也沒有相關的探討。因此本人由政策面,經濟面,社會面,以及科技面來見識這個產業,同時也網羅中國,墨西哥和韓國等國家在此幹細胞旅遊的發展實況。此研究包括各種幹細胞在臨床運用上的優劣面分析,以及價值鏈分析剖析自體幹細胞與異體幹細胞相關的治療模式下主要及支持性的活動。為了瞭解台灣發展幹細胞旅遊業的潛力,本人也訪問了台灣的幹細胞學者及專家,獲得建議低風險及聚集的治療為發展關鍵的結論,當中又以自體脂肪幹細胞隆乳為可行性項目,最重要的是,台灣應該要在醫療項目上有法規的品管透明化要求以建聲譽。總結而言,本研究的意義在於提供幹細胞產業相關人士在有興趣從事幹細胞旅遊業發展時能有一個全盤的檢視的參考依據。 | zh_TW |
dc.description.abstract | Stem cell tourism is a new term used to describe a situation where legal regulation of stem cell related industry is less clear, therefore private clinics have started to offer stem cell treatment and therefore attracted patients all over the world to seek for medical help, even though some of the procedures are still questionable in terms of safety and efficacy. However, no analysis has been performed to evaluate the global trend of this new industry and how might Taiwan stand in this emerging business opportunities and threats.
In this study, I used PEST (acronym for political, economic, social and technological analysis) to examine the important factors that are affecting this evolving industry. Meanwhile, information on how China, Mexico, and Korea poured investment to meet the demand of international patients is included. I also conducted an analysis to pinpoint the pros and cons of commercialization different types of stem cell products. In addition, value chain analysis is done to elucidate the core and supporting activities of autologous and allogenic stem cell-related treatment. I tried to evaluate the potential of Taiwan in developing stem cell tourism by conducting interviews with Taiwanese stem cell experts, private clinic owner, and Taiwan government officials. The most critical key success factor is concluded on the choice of low risk and focused therapy. Per the results of interview, the most suitable stem cell product and service for the first step development could be autologous fat tissue derived-stem cells for breast augmentation. The most promising way to improve the quality and transparency of stem cell usage relies on reasonable legal control and regulatory design. Collectively, the significance of this study is to form a holistic review for the stem cell business stakeholders who have interest in engaging in Taiwan stem cell tourism industry. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T00:40:46Z (GMT). No. of bitstreams: 1 ntu-100-R99749001-1.pdf: 1717599 bytes, checksum: 1243a44bf14f385ccbbbe8be205b7809 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | Table of content
Master Thesis Certification……...……………………………………………………..i Acknowledgement and dedication…………………………………………………….ii Chinese Abstract………………………………………………………………………iii English Abstract………………………………………………………………………..iv List of Figures…………………………………………………………………………..v List of Tables…………………………………………………………………………...vi Chapter 1: Introduction………………………………………………………………..1 1.1 Background………………………………………………………………………….1 1.2 Statement of problem………………………………………………………………...3 1.3 Research process……………………………………………………………………..4 Chapter 2: Literature review…………………………………………………………..6 2.1 Background information of stem cell biology……………………………………….6 2.2 Stem cells and regenerative medicine……………………………………………….6 2.2.1. embryonic stem cells………………………………………………………….7 2.2.2 adult stem cells………………………………………………………………...9 2.2.3. induced pluripotent stem cells……………………………………………….14 2.2.4. Therapeutic potential of stem Cells………………………………………….16 2.2.5. Stem cell therapies that are scientifically and clinically proven…………….17 2.2.6. Developmental Stem Cell Therapy…………………………………………..21 Chapter 3: Industry analysis of stem cell tourism…………………………………..29 3.1. The development of stem cell tourism-PEST……………………………………...29 3.2 Key country and industry players of stem cell tourism…………………………….37 3.3 Analysis of challenges of stem cell treatment in USA……………………………..45 3.4. Stem cell product analysis…………………………………………………………48 3.5. Value chain analysis on stem cell tourism…………………………………………53 Chapter 4: Potential of development of stem cell tourism: What does Taiwan have?...............................................................................................................................58 4.1. Current situation of medical tourism in Taiwan…………………………………...58 4.2. Taiwan has been a slower mover in the international medical tourism game……..62 4.3 Porter's Diamond of National Advantage: analysis of stem cell tourism in Taiwan.63 Chapter 5: Interview with stem cell scientist and physician for the opportunity of potential stem cell products…………………………………………………………..67 5.1. Approach…………………………………………………………………………...67 5.2. Summary of interview results……………………………………………………...69 Chapter 6: Conclusion and recommendations………………………………………75 6.1. Conclusion…………………………………………………………………………75 6.2. Current technology of using fat-derived stem cells for breast augmentation……...76 6.3. Strategy designs for promoting stem cell tourism in Taiwan……………………...78 References……………………………………………………………………………...90 Appendix A-Transcript of interview Researcher 1………………………………….94 Appendix B-Transcript of interview Researcher 2………………………………….97 Appendix C-Transcript of interview Researcher 3……………………………… .100 Appendix D-Transcript of interview Researcher 4 and 5…………………………103 | |
dc.language.iso | en | |
dc.title | 台灣幹細胞醫療旅遊業競爭策略研究 | zh_TW |
dc.title | Competitive Strategy Analysis of Taiwan Stem Cell Tourism | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林修葳,許瑋元 | |
dc.subject.keyword | 幹細胞醫療旅遊業,策略研究,風險,自體幹細胞,異體幹細胞, | zh_TW |
dc.subject.keyword | Stem cell tourism,competitive analysis,risk management,autologous stem cells,allogenic stem cells, | en |
dc.relation.page | 106 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2012-01-19 | |
dc.contributor.author-college | 管理學院 | zh_TW |
dc.contributor.author-dept | 企業管理碩士專班 | zh_TW |
顯示於系所單位: | 管理學院企業管理專班(Global MBA) |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 1.68 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。